DK0698091T3 - Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser op - Google Patents
Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser opInfo
- Publication number
- DK0698091T3 DK0698091T3 DK94916385T DK94916385T DK0698091T3 DK 0698091 T3 DK0698091 T3 DK 0698091T3 DK 94916385 T DK94916385 T DK 94916385T DK 94916385 T DK94916385 T DK 94916385T DK 0698091 T3 DK0698091 T3 DK 0698091T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- organism
- immunogens
- fragments
- derivatives
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 102000015636 Oligopeptides Human genes 0.000 abstract 2
- 108010038807 Oligopeptides Proteins 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000012795 verification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM930301A IT1270939B (it) | 1993-05-11 | 1993-05-11 | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
| PCT/IT1994/000054 WO1994026886A2 (en) | 1993-05-11 | 1994-05-05 | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0698091T3 true DK0698091T3 (da) | 1999-06-07 |
Family
ID=11401749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94916385T DK0698091T3 (da) | 1993-05-11 | 1994-05-05 | Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser op |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US5994083A (it) |
| EP (1) | EP0698091B1 (it) |
| JP (1) | JP2813468B2 (it) |
| CN (1) | CN1093881C (it) |
| AT (1) | ATE170558T1 (it) |
| AU (1) | AU685121B2 (it) |
| BR (1) | BR9406595A (it) |
| CA (1) | CA2160486C (it) |
| DE (1) | DE69413024T2 (it) |
| DK (1) | DK0698091T3 (it) |
| ES (1) | ES2120046T3 (it) |
| HK (1) | HK1011710A1 (it) |
| IT (1) | IT1270939B (it) |
| RU (1) | RU2136697C1 (it) |
| WO (1) | WO1994026886A2 (it) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492807A (en) | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
| JP3830525B2 (ja) * | 1995-11-10 | 2006-10-04 | サイトジェン，コーポレーション | 組織横断輸送を強化するペプチドとその同定法および使用法 |
| US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| FR2762601B3 (fr) | 1997-04-29 | 1999-06-04 | Bio Merieux | Polypeptide capable de reagir avec les anticorps de patients atteints de sclerose en plaques et utilisations |
| IT1291913B1 (it) * | 1997-05-22 | 1999-01-21 | Angeletti P Ist Richerche Bio | Metodo che prevede l'uso di batteriofagi per la rivelazione della presenza di molecole di interesse in campioni biologici |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| WO1999033969A1 (en) * | 1997-12-31 | 1999-07-08 | Pincus Seth H | A method of isolating a peptide which immunologically mimics microbial carbohydrates including group b streptococcal carbohydrates and the use thereof in a vaccine |
| GB9810756D0 (en) | 1998-05-19 | 1998-07-15 | Angeletti P Ist Richerche Bio | Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
| US6413721B1 (en) | 1998-07-24 | 2002-07-02 | Her Majesty the Queen in Right of Canada, as represented by the “Canadian Food Inspection Agency” | Methods of isolating common and specific antigens from excretory-secretory products of protostrongylidae |
| SE9803993D0 (sv) * | 1998-11-23 | 1998-11-23 | Bjoern Carlsson | New reagent and use thereof |
| GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US9974847B2 (en) * | 2000-08-24 | 2018-05-22 | Immunitor USA, Inc. | Treatment and prevention of tuberculosis |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| CA2461380C (en) | 2001-10-11 | 2011-03-22 | Merck & Co., Inc. | Hepatitis c virus vaccine |
| CN101988071B (zh) | 2001-10-11 | 2016-07-06 | 默沙东公司 | 丙型肝炎病毒疫苗 |
| US20050019751A1 (en) * | 2001-11-09 | 2005-01-27 | Riccardo Cortese | Screening for hepatitis c virus entry inhibitors |
| WO2003074003A2 (en) * | 2002-03-01 | 2003-09-12 | Applied Immune Technologies | Immunogens for treatment of neoplastic and infectious disease |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| WO2004098529A2 (en) * | 2003-04-30 | 2004-11-18 | Emory University | Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules |
| TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
| WO2006133911A2 (en) | 2005-06-17 | 2006-12-21 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hepatitis c virus nucleic acid vaccine |
| WO2007087758A2 (es) * | 2006-01-31 | 2007-08-09 | Centro De Ingenieria Genetica Y Biotecnologia | Mimotopos de polisacáridos capsulares de neisseria meningitidis y formulaciones farmacéuticas |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| FR2910492B1 (fr) | 2006-12-20 | 2013-02-15 | Bio Modeling Systems Ou Bmsystems | Procede de preparation de bacteriophages modifies par insertion de sequences aleatoires dans les proteines de ciblage desdits bacteriophages |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| EP2158220B1 (en) * | 2007-06-26 | 2017-04-19 | F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H | Display of binding agents |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| CN114230632B (zh) * | 2021-09-18 | 2023-01-24 | 华南农业大学 | 一种丙烯酰胺衍生物模拟表位肽及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575495A (en) * | 1983-05-12 | 1986-03-11 | New York Blood Center, Inc. | Synthetic antigenic peptide derived from Hepatitis B surface antigen |
| JPH07119760B2 (ja) * | 1984-07-24 | 1995-12-20 | コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション | ミモトープを検出または決定する方法 |
| US4751181A (en) * | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
| WO1986006487A1 (en) * | 1985-04-22 | 1986-11-06 | Commonwealth Serum Laboratories Commission | Method for determining mimotopes |
| US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5182366A (en) * | 1990-05-15 | 1993-01-26 | Huebner Verena D | Controlled synthesis of peptide mixtures using mixed resins |
| ES2109945T3 (es) * | 1990-06-01 | 1998-02-01 | Chiron Corp | Composiciones y procedimientos para identificar moleculas biologicamente activas. |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| IL99552A0 (en) * | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| IL99553A0 (en) * | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same |
| GB9022190D0 (en) * | 1990-10-12 | 1990-11-28 | Perham Richard N | Immunogenic material |
| DE4122599C2 (de) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5492807A (en) * | 1993-11-19 | 1996-02-20 | Santi; Daniel V. | Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease |
-
1993
- 1993-05-11 IT ITRM930301A patent/IT1270939B/it active IP Right Grant
-
1994
- 1994-05-05 WO PCT/IT1994/000054 patent/WO1994026886A2/en active IP Right Grant
- 1994-05-05 RU RU95122726A patent/RU2136697C1/ru active
- 1994-05-05 ES ES94916385T patent/ES2120046T3/es not_active Expired - Lifetime
- 1994-05-05 CA CA002160486A patent/CA2160486C/en not_active Expired - Lifetime
- 1994-05-05 AT AT94916385T patent/ATE170558T1/de active
- 1994-05-05 DK DK94916385T patent/DK0698091T3/da active
- 1994-05-05 BR BR9406595A patent/BR9406595A/pt not_active Application Discontinuation
- 1994-05-05 JP JP6525217A patent/JP2813468B2/ja not_active Expired - Lifetime
- 1994-05-05 EP EP94916385A patent/EP0698091B1/en not_active Expired - Lifetime
- 1994-05-05 DE DE69413024T patent/DE69413024T2/de not_active Expired - Lifetime
- 1994-05-05 US US08/553,257 patent/US5994083A/en not_active Expired - Lifetime
- 1994-05-05 CN CN94192060A patent/CN1093881C/zh not_active Expired - Lifetime
- 1994-05-05 AU AU68069/94A patent/AU685121B2/en not_active Expired
-
1998
- 1998-12-08 HK HK98112929A patent/HK1011710A1/xx not_active IP Right Cessation
-
1999
- 1999-11-18 US US09/441,992 patent/US6541210B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM930301A1 (it) | 1994-11-11 |
| WO1994026886A2 (en) | 1994-11-24 |
| JPH08506493A (ja) | 1996-07-16 |
| JP2813468B2 (ja) | 1998-10-22 |
| CN1122613A (zh) | 1996-05-15 |
| AU685121B2 (en) | 1998-01-15 |
| ATE170558T1 (de) | 1998-09-15 |
| BR9406595A (pt) | 1996-01-02 |
| RU2136697C1 (ru) | 1999-09-10 |
| DE69413024T2 (de) | 1999-02-04 |
| US5994083A (en) | 1999-11-30 |
| ITRM930301A0 (it) | 1993-05-11 |
| EP0698091B1 (en) | 1998-09-02 |
| CA2160486A1 (en) | 1994-11-24 |
| DE69413024D1 (de) | 1998-10-08 |
| HK1011710A1 (en) | 1999-07-16 |
| IT1270939B (it) | 1997-05-26 |
| CA2160486C (en) | 2001-02-13 |
| EP0698091A1 (en) | 1996-02-28 |
| WO1994026886A3 (en) | 1995-03-16 |
| CN1093881C (zh) | 2002-11-06 |
| ES2120046T3 (es) | 1998-10-16 |
| AU6806994A (en) | 1994-12-12 |
| US6541210B1 (en) | 2003-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0698091T3 (da) | Fremgangsmåde til fremstilling af immunogener eller diagnostiske reagenser samt immunogener eller diagnostiske reagenser op | |
| WO1994026886B1 (en) | Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable | |
| RU95122726A (ru) | Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью | |
| Legutki et al. | A general method for characterization of humoral immunity induced by a vaccine or infection | |
| NO924780L (no) | Ekspresjon av spesifikke immunogener ved bruk av virusantigener | |
| KR870010189A (ko) | HTLV-Ⅲgag/ env 유전자 단백질의 발현 및 정제 | |
| AR052377A2 (es) | Polipeptidos y polinucleotidos de neisseria meningitidis, un huesped unicelular, un metodo para producir una secuencia de adn, un metodo para producir un polipeptido, un metodo para aislar el antigeno, una composicion farmaceutica, uso de una proteina para producir una vacuna destinada para la preve | |
| WO2001088162A3 (en) | Methods and vectors for generating antibodies in avian species and uses therefor | |
| DK1114864T4 (da) | Pattedyrcelleoverfladeantigener samt tilhørende reagenser | |
| KR960701645A (ko) | 면역원성 종양 단백질 및 펩타이드, 및 이의 사용방법(Immunogenic cancer proteins and peptides and method of use) | |
| CN114702578B (zh) | 新型冠状病毒Omicron突变株特异性抗体及其应用 | |
| HUE034632T2 (en) | Improved vaccine diagnostics | |
| Mamula et al. | An immunological determinant of RNase P protein is conserved between Escherichia coli and humans. | |
| CN115286712A (zh) | 新型冠状病毒Delta突变株特异性抗体及其应用 | |
| Zhong et al. | Antigenic analysis of the chlamydial 75-kilodalton protein | |
| CN106939034B (zh) | 用于鉴定受试者所感染的hev基因型的方法和试剂盒 | |
| EP0331514A3 (en) | Assaying the duchenne muscular dystrophy protein deletion or defect | |
| CN116355094B (zh) | 抗小鼠白介素12的单克隆抗体及制备方法 | |
| CN112094352A (zh) | 一种抗IgM单克隆抗体 | |
| Yu et al. | Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice | |
| CN114075270B (zh) | 一种人源包虫病抗原的重组蛋白及其应用 | |
| Bradbury | The use of phage display in neurobiology | |
| Whyte et al. | Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system | |
| CN116284363B (zh) | 新型冠状病毒OmicronBA.2/4/5突变株特异性抗体及其应用 | |
| Meulen et al. | Immunhistological, microscopical and neurochemical studies on encephalitides. |